Not logged in.png)
Share.png)
SaveShare Save Share Save Share Save Share Save Share Save Share Save Share Save Long-term outcomes of imiglucerase treatment in children withGaucher disease type 1 or type 3 starting therapy before the age of2 years
Mistry, Pramod K.; Carwile, Jenny L.; Burrow, Andrew; Ganesh, Jaya; Camelo Jr, Jose Simon; Hennermann, Julia B.; Batista, Julie L.; Oliveira-dos-Santos, Antonio; Perichon, Maria G.; Tantawy, Azza Share Save Acid sphingomyelinase deficiency and Gaucher disease: Underdiagnosed and often treatable causes of hepatomegaly, splenomegaly, and low HDL cholesterol in lean individualsMistry, Pramod K.; Cassiman, David; Jones, Simon A.; Lachmann, Robin; Lukina, Elena; Prada, Carlos E.; Wasserstein, Melissa P.; Thurberg, Beth L.; Foster, Meredith C.; Patel, Reema M.; Underhill, Lisa H.; Peterschmitt, M. Judith Share Save Share Save Long-term effectiveness of eliglustat treatment: A real-world analysis from the International Collaborative Gaucher Group Gaucher RegistryMistry, Pramod K.; Balwani, Manisha; Charrow, Joel; Lorber, Jeremy; Niederau, Claus; Carwile, Jenny L.; Oliveira-dos-Santos, Antonio; Perichon, Maria Gabriela; Uslu Cil, Sefika; Kishnani, Priya S. Share Save Share Save Share Save Share Save Share Save Share Save Share Save Osteonecrosis in Gaucher disease in the era of multiple therapies: Biomarker set for risk stratification from a tertiary referral centerBasiri, Mohsen; Ghaffari, Mohammad E.; Ruan, Jiapeng; Murugesan, Vagishwari; Kleytman, Nathaniel; Belinsky, Glenn; Akhavan, Amir; Lischuk, Andrew; Guo, Lilu; Klinger, Katherine; Mistry, Pramod K. Share Save Share Save 
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
